<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02000609</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-01535BC1-02</org_study_id>
    <nct_id>NCT02000609</nct_id>
  </id_info>
  <brief_title>A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of &quot;Nexthaler&quot; Dry Powder Inhaler in COPD Patients</brief_title>
  <acronym>NEXThaler</acronym>
  <official_title>Phase II, Partial Blind, Randomized, Placebo Controlled, 5-way Cross-over Study to Evaluate the Pharmacodynamics of BDP(Beclomethasone Diproprionate)/B17MP (Beclomethasone-17-Monoproprionate) and FORMOTEROL FUMARATE (FF) Across Two Different Dose Levels of CHF 1535 NEXThaler DPI (Dry Powder Inhaler) and CHF 1535 pMDI (Pressurized Metered-dose Inhaler)in Adult COPD (Chronic Obstructive Pumonary Disease) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim is to compare the pharmacodynamic effects (cardiovascular effects- primary&#xD;
      variable: Heart rate over 4 hours post dosing- ) after administration of BDP and formoterol&#xD;
      administered as CHF 1535 100/6 NEXThaler DPI or CHF1535 pMDI at two different dose levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of both formulations on serum potassium and serum glucose and the general safety&#xD;
      and tolerability of study treatments will be also evaluated&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average 4-hour Heart Rate bpm (beats per minutes)</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcF (QT interval Fridericia's formula corrected) (milliseconds), QRS (milliseconds) and PR (milliseconds) intervals, PAC (Premature Atrial Contraction- percentage) burden, PVC (Premature Ventricular Contraction-percentage) burden, Blood Pressure (mmHg)</measure>
    <time_frame>-45, -30, -15min pre-dose, 5, 10, 20, 30, 45min, 1, 1.5, 2, 3, 4, 5, 5, 7, 8, 10 12 hr post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>CHF 1535 NEXThaler 800/48 ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose administration of CHF 1535 100/6 NEXThaler DPI, total dose: 800ug BDP, 48 ug Formoterol Fumarate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 1535 NEXThaler PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose administration of placebo via NEXThaler DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 1535 pMDI 200/12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose administration of CHF 1535 100/6 pMDI , total dose: 200 ug BDP, 12 ug Formoterol Fumarate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 1535 100/6 pMDI 800/48</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose administration of CHF 1535 100/6 pMDI total dose: 800ug BDP, 48 ug Formoterol Fumarate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 1535 NEXThaler 200/12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose administration of CHF 1535 100/6 pMDI, total dose: 200 ug BDP, 12 ug Formoterol Fumarate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 NEXThaler 800/48</intervention_name>
    <arm_group_label>CHF 1535 NEXThaler 800/48 ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 NEXThaler 200/12</intervention_name>
    <arm_group_label>CHF 1535 NEXThaler 200/12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 NEXThaler PLACEBO</intervention_name>
    <arm_group_label>CHF 1535 NEXThaler PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 pMDI 200/12</intervention_name>
    <arm_group_label>CHF 1535 pMDI 200/12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF1535 pMDI 800/48</intervention_name>
    <arm_group_label>CHF 1535 100/6 pMDI 800/48</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults (≥ 40 and ≤ 75 years old).&#xD;
&#xD;
          -  Outpatients with diagnosis of moderate/severe stable COPD, according to GOLD (Global&#xD;
             Initiative for Chronic Obstructive Lung Disease) guidelines update 2013 at least in&#xD;
             the 6 months before the screening visit.&#xD;
&#xD;
          -  A post-bronchodilator FEV1(Forced Expiratory Volume in one second) ≥ 40 and &lt; 80% of&#xD;
             the predicted normal value and FEV1/FVC (Forced Vital Capacity) &lt; 0.7, after 4 puffs&#xD;
             (4 x 100 µg) of salbutamol pMDI. If this criterion is not met at screening, the test&#xD;
             can be repeated once before commencing of the run-in period.&#xD;
&#xD;
          -  Ability to use pMDI (pressured metered-dose inhaler)and DPI (dry powder Inhaler)&#xD;
             devices&#xD;
&#xD;
          -  Current or past smoker of at least 10 pack/years where one pack-year is equivalent to&#xD;
             20 cigarettes per day for 1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating female subjects.&#xD;
&#xD;
          -  Current diagnosis of Asthma (as defined by the current GINA (Global Initiative for&#xD;
             Asthma guidelines 2012 (update), or history of allergic rhinitis.&#xD;
&#xD;
          -  COPD exacerbations requiring systemic steroids and /or antibiotics and/or oral or&#xD;
             nebulized beta 2-agonists in the 4 weeks prior to screening and until randomization.&#xD;
&#xD;
          -  Lower Respiratory Tract Infection (LRTI) in the 4 weeks prior to screening and until&#xD;
             randomization.&#xD;
&#xD;
          -  Patients with serum potassium levels &lt; 3.5 mEq/L (milliequivalent per liter).&#xD;
&#xD;
          -  History of substance abuse or drug abuse within 12 months prior to screening visit.&#xD;
&#xD;
          -  Known respiratory disorders other than COPD including but not limited to α1&#xD;
             antitrypsin deficiency, active tuberculosis, bronchiectasis, sarcoidosis, lung&#xD;
             fibrosis, pulmonary hypertension, restrictive lung disease and interstitial lung&#xD;
             disease.&#xD;
&#xD;
          -  Intolerance or contra-indication to treatment with beta 2-agonists and/or inhaled&#xD;
             corticosteroids or allergy to any component of the study treatments.&#xD;
&#xD;
          -  Patients treated with non-cardioselective β-blockers in the month preceding the&#xD;
             screening visit or during the study period.&#xD;
&#xD;
          -  Patients who have clinically significant cardiovascular disease according to&#xD;
             investigator's judgement. Thus includes but is not limited to:&#xD;
&#xD;
               -  congestive heart failure (NYHA class &gt; 3);&#xD;
&#xD;
               -  acute ischemic heart disease within the past 12 months of screening;&#xD;
&#xD;
               -  Sustained cardiac arrhythmias (supraventricular or ventricular, &gt;30 seconds&#xD;
                  duration) at or within 6 months of screening;&#xD;
&#xD;
               -  Non sustained cardiac arrhythmias (supraventricular or ventricular, &gt; 3 beats &lt;&#xD;
                  30 seconds and or ending spontaneously and or asymptomatic);&#xD;
&#xD;
               -  History of sustained and non-sustained cardiac arrhythmias (supraventricular or&#xD;
                  ventricular);&#xD;
&#xD;
               -  2nd or 3rd degree Atrioventricular conduction block;&#xD;
&#xD;
               -  Left Bundle Branch Block.&#xD;
&#xD;
          -  An abnormal 12-lead ECG (QRS&gt; 120 msec, PR&gt; 220 msec, HR &lt; 40 bpm, Heart Rate &gt; 110&#xD;
             bpm) at screening or at randomization.&#xD;
&#xD;
          -  Patients whose electrocardiogram (12-lead ECG) shows QTcF &gt;450 ms for males or QTcF &gt;&#xD;
             470 ms for females at screening or at randomisation.&#xD;
&#xD;
          -  Patients whose DBP/SBP is higher than: DBP 90 mmHg or SBP 160 mmHg at screening or at&#xD;
             randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicine Evaluation Unit, Manchester (UK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicine Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M239Qz</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002966-38</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <link>
    <url>https://www.chiesi.com/clinic/CSR_Synopsis_CCD-01535BC1-02.pdf</url>
    <description>CSR Synopsis available in the CHIESI Clinical Study Register</description>
  </link>
  <results_reference>
    <citation>Singh D, Ciurlia G, Piccinno A, Muraro A, Bocchi M, Scuri M. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study. Pulm Pharmacol Ther. 2017 Feb;42:43-51. doi: 10.1016/j.pupt.2016.12.004. Epub 2017 Jan 5.</citation>
    <PMID>28065679</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>November 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2013</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacodynamics COPD</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

